Date(s) - June 1,2018 - June 3,2018
8:00 am - 1:00 pm
Westin Georgetown Washington DC
Dr. Gregory Holmquist, Pharm D., CPE
Certified Pain Educator
Dr. Gregory Holmquist is a pain and palliative care specialist. He is on the Board of Advisors of the American Society of Pain Educators. Over the past two decades, Greg has been invited to present over 2000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
Friday, June 1, 2018
1. State three key ethnic, cultural, ethical, or legal issues surrounding the use of opioids in managing acute, chronic, and end-of-life pain and how health care providers can play a key role in addressing these issues.
2. Describe the key features of the REMS recommendations of the FDA for opioids.
3. State the definitions of “addiction”, “dependency”, “tolerance”, and “hyperalgesia” and how to prevent/minimize each of these from negatively influencing the care of patients who are receiving opioids.
4. Describe various tamper resistant opioid products on the market.
5. Differentiate the patient/chronic pain syndrome which can benefit from a trial of opioid therapy and be able to implement this therapeutic approach in a manner that minimize the risks of drug diversion, addiction, and side effects.
6. Compare and contrast the pharmacology, pharmacokinetics, side effects, and clinical utilization of the commercially available opioid products.
7. State the similarities and differences in the principles for the use of opioids in patients who have chronic non-cancer pain and those who have end-of-life pain.
8. Identify three characteristics of patients who would be identified as “high risk”, “moderate risk”, and “low risk” for chronic opioid use and how to properly monitor these patients when they are receiving long-term opioid therapy for chronic pain.
9. State three reasons why opioids may not be effective for some patients with chronic pain.
10. State three alternative therapeutic modalities for pain that is unresponsive to opioid therapies.
11. State the most common side effects that patients may experience from opioid therapy and how to prevent and/or treat each of them.
Dr. Renee Jones, Pharm D.
Nova Southeastern University
Renee Greaves currently serves as the Director of Preceptor Development as Assistant Professor at Nova Southeastern University in Ft. Lauderdale, Florida. She has served as the Pharmacy Operations Supervisor and Residency Coordinator of Broward Health, where she implemented clinical pharmacy programs such as HIV and antibiotic stewardships, hepatic monitoring, cardiopulmonary discharge counseling, and internal medicine clinical rounds with graduate medical education residents. She has also served as a Clinical Assistant Professor of Rutgers University School of Pharmacy where she taught didactic courses such as Infectious Disease Therapeutics and numerous electives.
Saturday June 2, 2018
ACPE # 0043-9999-17-057-L01-P
1. Discuss the clinical indications for the new medications approved by the FDA.
2. Explain the various mechanisms of action for the medications discussed within this program.
3. Recognize the clinically relevant drug interactions for the medications.
4. Identify the most common adverse reactions for the new drug approvals.
5. Explain the approved dosing guidelines and recommended dosage adjustments for the medications reviewed.
Dr. Virgil Van Dusen, RPh, JD
Southwestern Oklahoma State University
Dr. Virgil Van Dusen is a professor of pharmaceutical sciences in the College of Pharmacy at Southwestern Oklahoma State University in Weatherford, Oklahoma. Prior to joining Southwestern, he practiced extensively as both a pharmacist and an attorney. Courses that he teaches include pharmacy law, ethics, and pharmacy administration. Dr. Van Dusen has authored numerous articles dealing with legal and management issues related to pharmacy practice and has a special interest in legal concerns for pharmacy education. He has presented research at both state and national conferences and is a frequently invited speaker for pharmacy organizations.
Sunday, June 3, 2018
ACPE# 0043-9999-18-013-L03-P and 0043-9999-18-014-L05-P
1. Identify significant federal legislationaffecting pharmacy practice.
2. List specific mandates of federal law which requires pharmacist action and compliance in order to avoid violations.
3. Explain how laws provide patient benefits and positive outcomes.
4. Understand causes for medication errors.
5. Describe methods to prevent medication errors, reduce risk associated with those errors and protect assets.